Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01377922 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3 study of Lambert-eaton Myasthenic Syndrome, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 38
- Enrollment target
- 14
- Study locations
NCT01377922: Completed Phase 3 study of Lambert-eaton Myasthenic Syndrome, sponsored by Catalyst Pharmaceuticals.
NCT01377922 is a Phase 3 study of Lambert-eaton Myasthenic Syndrome that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 38 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). The trial reports 14 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01377922, a Phase 3 study of Lambert-eaton Myasthenic Syndrome, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 38 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Primary Outcome
The QMG is a physician-rated test including 13 assessments, including facial strength, swallowing, grip strength, and duration of time that limbs can be maintained in outstretched positions. Each of the 13 items is scored from 0 (none) to 3 (severe). The total score can range from 0 to 39. Increased QMG total score correlates to worsening symptoms of LEMS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Amifampridine Phosphate
Study Locations (14)
Other
- - Lyon
- - Berlin
- - Pécs
- - Warsaw
- - Moscow
- - Belgrade
- - Madrid
California
- - Los Angeles
- - Palo Alto
Alabama
- - Birmingham
Arizona
- - Scottsdale
Kansas
- - Kansas City
New York
- - New York
Bavaria
- - Munich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
What the finished NCT01377922 record still lists
NCT01377922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Lambert-eaton Myasthenic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01377922 lists 14 locations in 7 states (Other, California, Alabama).
Frequently Asked Questions
What is clinical trial NCT01377922 about?
NCT01377922 is a clinical study titled "A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)". A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
What is the current status of trial NCT01377922?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 38 participants. The study started on 2011-06. Estimated completion is 2016-07.
What conditions does trial NCT01377922 study?
This clinical trial studies the following conditions: Lambert-eaton Myasthenic Syndrome.
What interventions are being tested in trial NCT01377922?
The interventions under investigation include: Placebo (DRUG), Amifampridine Phosphate (DRUG).
Who is sponsoring clinical trial NCT01377922?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01377922 being conducted?
This trial has 14 study locations across Alabama, Arizona, California, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lambert-eaton Myasthenic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01377922's enrollment target sits among peer trials
38 1900th of 2000 higher than 100 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia